|1.||Woods, Gail L: 19 articles (06/2004 - 01/2002)|
|2.||Abramson, Murray A: 11 articles (04/2009 - 08/2005)|
|3.||Teppler, Hedy: 11 articles (08/2005 - 01/2002)|
|4.||Gesser, Richard M: 11 articles (06/2004 - 01/2002)|
|5.||Goldstein, Ellie J C: 9 articles (04/2009 - 04/2002)|
|6.||Citron, Diane M: 8 articles (04/2009 - 04/2002)|
|7.||Ko, Wen-Chien: 7 articles (04/2015 - 11/2010)|
|8.||Hawser, Stephen P: 7 articles (06/2013 - 08/2010)|
|9.||Hoban, Daryl J: 7 articles (06/2013 - 02/2005)|
|10.||Burkhardt, Olaf: 7 articles (01/2010 - 06/2005)|
06/01/2014 - "This study has shown that ertapenem is not a suitable alternative for first-line treatment for gonorrhoea but that it may be useful for the treatment of highly resistant infections."
01/01/2014 - "Ertapenem has been demonstrated to be highly effective for the treatment of complicated infections. "
01/01/2003 - "[Efficacy of invanz proven in the treatment of intra-abdominal infections in one of the largest studies yet conducted on surgical patients]."
07/01/2010 - "Ertapenem administration through OPAT may help to decrease the costs associated with ESBL infections by reducing the number of inpatient bed days required for their successful treatment."
01/01/2007 - "Clinical outcomes studies are needed to determine if ertapenem is effective for the treatment of infection caused by these organisms. "
10/01/2015 - "A 4-week course of intravenous ertapenem was administered, and the pneumatocele with pneumonia resolved on follow-up chest CT. "
11/01/2009 - "Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population."
12/01/2006 - "In vitro data suggest that ertapenem could be a useful treatment option for community-acquired pneumonia."
06/01/2005 - "Ertapenem is approved for the treatment of community-acquired pneumonia (CAP), but its in vivo penetration into lung tissue (LT), epithelial lining fluid (ELF), and alveolar cells (AC) is unknown. "
06/01/2004 - "Ertapenem was highly active against most of the pathogens isolated from patients with community-acquired pneumonia, except for isolates of methicillin-resistant S. "
09/01/2007 - "Ertapenem, a group I carbapenem antibiotic, has been shown to be safe and effective in treating adults with complicated intra-abdominal (cIAI) or acute pelvic infection (API). "
11/01/2002 - "Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection."
01/01/2009 - "Ertapenem, a new carbapenem with a favorable pharmacokinetic profile, has been approved for the treatment of complicated intra-abdominal Infections (cIAIs), acute pelvic infections (APIs) and complicated skin and skin-structure infections (cSSSIs). "
01/01/2003 - "Ertapenem has a role in the treatment of CAP associated with typical respiratory pathogens and is of particular value in the treatment of polymicrobial infections (such as CIAI, CSSSI, CUTI and acute pelvic infections), especially where Enterobacteriaceae and anaerobic bacteria are involved."
10/01/2007 - "Ertapenem is indicated for complicated intra-abdominal, skin and skin-structure, urinary tract and acute pelvic infections as well as community-acquired pneumonia, for which there are cheaper and more narrow-spectrum antibiotics. "
|4.||Urinary Tract Infections (Urinary Tract Infection)
09/01/2014 - "The objective of this study was to determine the pharmacokinetics and renal disposition of ertapenem in outpatients with complicated urinary tract infections. "
12/01/2015 - "All patients received renal adjusted doses of ertapenem for complicated urinary tract infection (UTI). "
01/01/2015 - "The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children."
09/01/2014 - "Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections."
09/01/2012 - "Ertapenem could be used to treat urinary tract infections (UTI) caused by ESBL producing enterobacteriacae (ESBL-E) and administered subcutaneously. "
01/01/2008 - "Ertapenem has limited efficacy against non-fermenting, Gram-negative bacteria, restricting its use to community-acquired infections. "
09/01/2010 - "The spectrum of ertapenem does not cover eminently nosocomial pathogens such as Pseudomonas aeruginosa and Acinetobacter spp., and hence this antibiotic is indicated in community-acquired infections requiring hospital treatment. "
10/01/2009 - "Ertapenem is suited for mild to moderately ill patients with community-acquired infections and for outpatient intravenous antibacterial therapy."
10/01/2007 - "Ertapenem is a new carbapenem, exhibiting activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria commonly recovered from community-acquired infections. "
02/01/2005 - "Ertapenem is a promising new carbapenem with excellent efficacy and safety for the treatment of a variety of community-acquired infections. "
|7.||Carbapenems (Carbapenem Antibiotics)
|2.||Renal Dialysis (Hemodialysis)
|3.||Renal Replacement Therapy (Therapies, Renal Replacement)
|4.||Length of Stay